Pharmacology of anticancer drugs in the elderly: Tools for dose-adjustment;Pharmacologie des agents anticancéreux chez le sujet âgé: Une aide à l'adaptation des doses

Bulletin du Cancer

Volumn 95, Issue SUPPL. 8, 2008, Pages

  Tranchand, Brigitte ^a,b,c   Falandry, Claire ^d   You, Benoît ^a,b,d   Girard, Pascale ^a,b   Ribba, Benjamin ^a,b   Tod, Michael ^a,b,e   Freyer, Gilles ^a,b,d  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^c CENTRE LÉON BÉRARD   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e Institut Cochin   (France)

Author keywords

Dose adaptation; Elderly; Pharmacodynamy; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DAUNORUBICINOL; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PLATINUM DERIVATIVE; PREDNISONE; PROCARBAZINE; TAXANE DERIVATIVE; TOPOTECAN; TRASTUZUMAB; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLORECTAL CANCER; COMORBIDITY; DAILY LIFE ACTIVITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; FRAIL ELDERLY; GERIATRIC PATIENT; HIGH RISK POPULATION; HUMAN; LIFE EXPECTANCY; LUNG CANCER; LYMPHATIC LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; MYELOID LEUKEMIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CANCER; REVIEW; SKIN TOXICITY; UNSPECIFIED SIDE EFFECT;

EID: 45849108329     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0541     Document Type: Review

References (46)

1. Freyer G, Braud AC, Chaibi P, Spielmann M, Martin JP, Vilela G, et al. Dealing with metastatic breast cancer in elderly women : results from a French study on a large cohort carried out by the Observatory on Elderly Patients. Ann Oncol 2006 ; 17 : 211-6.
2. Balducci L. Cancer chemotherapy in elderly cancer patients. Oncol Manag 2005 ; 14 : 35-8.
3. Tranchand B, Laporte S, Glehen O, Freyer G. Pharmacology of cytotoxic agents : a helpful tool for building dose adjustment guidelines in the elderly. Crit Rev Oncol Hematol 2003 ; 48 : 199-214.
4. Wildiers H, Highley MS, de Bruijn EA, van Oosterom AT. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 2003 ; 42 : 1213-42.
5. Balducci L. The geriatric cancer patient : equal benefit from equal treatment. http ://moffitt.org/moffittapps/ccj/index.html. Cancer Control 2001; 1-25.
6. Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Thurlimann B, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer : The International Breast Cancer Study Group Trial VII. J Clin Oncol 2000 ; 18 : 1412-22.
7. Moore JO, Dodge RK, Amrein PC, Kolitz J, Lee EJ, Powell B, et al. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with azitidinyl benzoquinone and mitoxantrone : Cancer and Leukemia Group B study 9022. Blood 1997 ; 89 : 780-8.
8. Hénin E, Zuideveld KP, Dartois C, Tranchand B, Freyer G, Girard PA. KPD Model for ordered categorical data : application to toxicity score in colorectal cancer patients treated with capecitabine. 2006 Page 15. www.page-meeting.org/?abstract=929
9. Cova D, Beretta G, Balducci L. Cancer chemotherapy in the older person. In : Balducci L, Lyman GH, Ershler WB, eds. Comprehensive geriatric oncology. Amsterdam, The Netherlands : Harwood Academic Publishers, 1998.
10. Balducci L, Parker M, Sexton W, Tantranond P. Pharmacology of antineoplastic agents in the elderly patient. Semin Oncol 1989 ; 16 : 76-84.
11. Sekine I, Fukuda H, Kunitoh H, Saijo N. Cancer chemotherapy in the elderly. Jpn J Clin Oncol 1998 ; 28 : 463-73.
12. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM. The effect of age on the pharmacokinetics of ifosfamide. Br J Clin Pharmacol 1990 ; 30 : 140-3.
13. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996 ; 31 : 47-64.
14. Miya T, Sasaki Y, Karato A, Saijo N. Pharmacokinetic study of mitomycin C with emphasis on the influence of aging. Jpn J Cancer Res 1992 ; 83 : 1382-5.
15. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease : the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982 ; 307 : 652-9.
16. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001 ; 24 : 19-38.
17. Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007 ; 43 : 14-34.
18. Bréchot JM, Pailler M, Morère JF. Lung cancer treatment in elderly patients. Bull Cancer 2007 ; 94 : 652-7.
19. Anchisi A, Anchisi S, Hugentobler V, Luyet V, Pott M. Accepting chemotherapy at the age of 70 and over: between autonomy and ageing. Bull Cancer 2006 ; 93 : 407-14.
20. Ando M, Minami H, Ando Y, Sakai S, Shimono Y, Sugiura S, et al. Pharmacological analysis of etoposide in elderly patients with lung cancer Clin Cancer Res 1999 ; 5 : 1690-5.
21. Meibohm B, Derendorf H . Basic concepts of pharmacokinetic/ pharmacodynamic (PK/PD) modeling. Int J Clin Pharmacol Ther 1997 ; 35 : 401-13.
22. Nguyen L, Chatelut E, Chevreau C, Tranchand B, Lochon I, Bachaud JM, et al. Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol 1998 ; 41 : 125-32.
23. Tranchand B, Amsellem C, Chatelut E, Freyer G, Iliadis A, Ligneau B, et al. A limited sampling strategy for estimating etoposide pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 1999 ; 43 : 316-22.
24. Testart-Paillet D, Girard P, You B, Freyer G, Pobel C, Tranchand B. Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. Crit Rev Oncol Hematol 2007 ; 63 : 1-11.
25. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine : a new prediction equation. Ann Intern Med 1999 ; 130 : 461-70.
26. Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001;84 : 452-9.
27. Marx GM, Blake GM, Galani E, Steer CB, Harper SE, Adamson KL, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004 ; 15 : 291-5.
28. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007 ; 25 : 1824-31.
29. Terret C., Albrand G, Jeanton M, Courpron P, Droz JP. What's new in geriatric oncology? Bull Cancer 2006 ; 93 : 119-23.
30. Freyer G, Geay JF, Touzet S, Provencal J, Weber B, Jacquin JP, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovatian carcinoma : a Gineco study. Ann Oncol 2005 ; 16 : 1795-800.
31. Henin E, You B, Tranchand B, Freyer G, Girard P. Issues of the study of patient compliance to treatment with oral anticancer chemotherapy : advantages of pharmacokinetics-pharmacodynamics modelisation. Therapie 2007; 62 : 77-85.
32. Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995 ; 87 : 573-80.
33. Matsui K, Masuda N, Yana T, Takada Y, Kobayashi M, Nitta T, et al. Carboplatin calculated with Chatelut's formula plus etoposide for elderly patients with small-cell lung cancer. Intern Med 2001 ; 40 : 603-6.
34. Fukuda M, Soda H, Soejima Y, Fukuda M, Kinoshita A, Takatani H, et al. A phase I trial of carboplatin and etoposide for elderly patients with small-cell lung cancer. Cancer Chemother Pharmacol 2006 ; 58 : 601-6.
35. Sorio R, Toffoli G, Crivellari D, Bearz A, Corona G, Colussi AM, et al. Oral etoposide in eldefly patients with advanced non small cell lung cancer: a clinical and pharmacological study. J Chemother 2006 ; 18 : 188-91.
36. Freyee G, Ligneau B, Tranchand B, Ardiet C, Souquet PJ, Court-Fortune I, et al. The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancet patients : a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thotacique (GLOT). Lung Cancer 2001 ; 31 : 247-56.
37. El-Yazigi A, Ezzat A, Berry J, Raines DA, Yusuf A, al-Rawithi S, et al. Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient. J Clin Pharmacol 2000 ; 40 : 153-60.
38. Nguyen L, Tranchand B, Puozzo C, Variol P. Population pharmacokinetics model and limited sampling strategy fot intravenous vinotelbine derived from phase I clinical trials. BrJ Clin Pharmacol 2002 ; 53 : 459-68.
39. Puozzo C, Gridelli C. Non-small-cell lung cancer in elderly patients : influence of age on vinorelbine oral pharmacokinetics. Clin Lung Cancer 2004 ; 5 : 237-42.
40. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998 ; 16 : 187-96.
41. Takigawa N, Segawa Y, Kishino D, Fujiwara K, Tokuda Y, Seki N, et al. Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients. Cancer Chemother Pharmacol 2004 ; 54 : 230-6.
42. ten Tije AJ, Verweij J, Carducci MA, Graveland W, Rogers T, Pronk T, et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 2005 ; 23 : 1070-7.
43. Ralph LD, Thomson AH, Dobbs NA, Twelves C. A population model of epirubicin pharmacokinetics and application to dosage guidelines. Cancer Chemother Pharmacol 2003 ; 52 : 34-40.
44. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-ovetexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998 ; 16 : 2659-71.
45. McKeage K, Perry CM. Trastuzumab : a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002 ; 62 : 209-43.
46. Lichtman SM, Wildiers H, Chatelut E, Steer C, Budman D, Morrison VA, et al. International Society of Geriatric Oncology Chemotherapy Taskforce. International Society of Geriatric Oncology Chemotherapy Taskforce : evaluation of chemotherapy in older patients : an analysis of the medical literature. J Clin Oncol 2007 ; 25 : 1832-43.